This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Epidemiological EMESIS-Registry (EMESIS)

This study has been completed.
Sponsor:
Collaborators:
Arbeitsgemeinschaft fur Internistische Onkologie
ASORS
Arbeitskreis Klinische Studien
Merck Sharp & Dohme Corp.
Information provided by (Responsible Party):
iOMEDICO AG
ClinicalTrials.gov Identifier:
NCT00911222
First received: May 28, 2009
Last updated: December 23, 2014
Last verified: December 2014
May 28, 2009
December 23, 2014
October 2008
May 2009   (Final data collection date for primary outcome measure)
Efficacy of anti-emetic therapies dependent on the rate "complete and major control" of nausea and emesis in moderately and highly emetogenic chemotherapy regimens. [ Time Frame: 4 chemotherapy applications per patient ]
Same as current
Complete list of historical versions of study NCT00911222 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
Epidemiological EMESIS-Registry
Epidemiologic Registry for the Description of Antiemetic Strategies Under Real-life Conditions.
The purpose of this registry is to record information on reality of anti-emetic therapies of cancer-patients in Germany. The outcome of this study is the efficacy of anti-emetic therapies dependent on the rate "complete and major control" of nausea and emesis in moderately and highly emetogenic chemotherapies, consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.
Not Provided
Observational
Observational Model: Cohort
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
Practitioners specialized in oncology, hematology and/or gynaecology
Antiemetic Therapy
Other: non-interventional
non-interventional
antiemetic treatment
epidemiological registry
Intervention: Other: non-interventional

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
1035
August 2009
May 2009   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Moderately or highly emetogenic chemotherapy consisting of platin-derivates (cisplatin, carboplatin and oxaliplatin), anthracyclines and/or cyclophosphamid.
  • start with the 1st cycle of the regimen (chemo naive patients). Inclusion of pretreated patients is also possible, if the last treatment cycle of a previous chemotherapy was given >= 24 months ago.
  • Compliance with registry procedures
  • Age >= 18 years
  • WHO Performance Status of 0 or 1 (Karnofsky-Index >= 70%)
  • Life expectancy of at least 12 weeks
  • Signed and dated informed consent before the start of the registry

Exclusion Criteria:

  • Mentally incapable or incompliant patients
  • Last chemotherapy <= 24 months (if pretreated)
  • Known hypersensitivity to antiemetic medication
  • unability of the patient to be treated with oral medication
  • pregnancy or lactation period
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Germany
 
 
NCT00911222
IOM-143
IOM-143
Not Provided
Not Provided
Not Provided
iOMEDICO AG
iOMEDICO AG
  • Arbeitsgemeinschaft fur Internistische Onkologie
  • ASORS
  • Arbeitskreis Klinische Studien
  • Merck Sharp & Dohme Corp.
Principal Investigator: Jan Schröder, Dr. med. / MD Praxis für Hämatologie und Onkologie
iOMEDICO AG
December 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP